Literature DB >> 19120529

Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.

Nobumichi Tanaka1, Isao Asakawa, Hideaki Kondo, Motoyoshi Tanaka, Kiyohide Fujimoto, Masatoshi Hasegawa, Noboru Konishi, Yoshihiko Hirao.   

Abstract

OBJECTIVES: To assess our initial experience in the treatment of localized prostate cancer using low-dose-rate brachytherapy (LDR-brachytherapy) with iodine-125.
METHODS: One-hundred consecutive patients received LDR-brachytherapy between July 2004 and October 2006. Seventy-six patients were treated with seed implantation alone, whereas 24 patients were treated with a combination of brachytherapy and external beam radiotherapy. The minimal percentage of the dose received by 90% of the prostate gland (%D90), the percentage prostate volume receiving 100% of the prescribed minimal peripheral dose (V100), and the operation time were compared among every 10 consecutive patients.
RESULTS: The means of %D90 and V100 were 109.6% and 93.4%, respectively. When compared with the first 10 patients, both D90 and V100 showed significant improvement in the following 10 consecutive patients. Similarly, the mean operation time decreased significantly according to the accumulated number of patients.
CONCLUSIONS: Our initial experience with the first 100 cases suggests that LDR-brachytherapy needs accumulation of many more patients to obtain high-quality post-implant dosimetric outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19120529     DOI: 10.1111/j.1442-2042.2008.02172.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

1.  Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.

Authors:  Nobumichi Tanaka; Isao Asakawa; Kiyohide Fujimoto; Satoshi Anai; Akihide Hirayama; Masatoshi Hasegawa; Noboru Konishi; Yoshihiko Hirao
Journal:  BMC Urol       Date:  2012-09-14       Impact factor: 2.264

2.  Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yoshihiro Tatsumi; Yasushi Nakai; Takeshi Inoue; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Urol       Date:  2017-08-14       Impact factor: 2.264

3.  Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.

Authors:  Nobumichi Tanaka; Isao Asakawa; Yasushi Nakai; Makito Miyake; Satoshi Anai; Tomomi Fujii; Masatoshi Hasegawa; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Cancer       Date:  2017-08-25       Impact factor: 4.430

4.  Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Nagaaki Marugami; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  J Contemp Brachytherapy       Date:  2017-07-27

5.  A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Kaori Yamaki; Takashi Inoue; Shota Suzuki; Shunta Hori; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Michihiro Toritsuka; Hitoshi Nakagawa; Shinji Tsukamoto; Tomomi Fujii; Chiho Ohbayashi; Masatoshi Hasegawa; Masato Kasahara; Kiyohide Fujimoto
Journal:  Contemp Clin Trials Commun       Date:  2020-06-17

6.  Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy.

Authors:  Nobumichi Tanaka; Isao Asakawa; Satoshi Anai; Akihide Hirayama; Masatoshi Hasegawa; Noboru Konishi; Kiyohide Fujimoto
Journal:  Radiat Oncol       Date:  2013-01-30       Impact factor: 3.481

7.  The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions.

Authors:  Nobumichi Tanaka; Isao Asakawa; Emiko Katayama; Akihide Hirayama; Masatoshi Hasegawa; Noboru Konishi; Kiyohide Fujimoto
Journal:  Radiat Oncol       Date:  2014-05-06       Impact factor: 3.481

8.  Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.

Authors:  Nobumichi Tanaka; Yasushi Nakai; Makito Miyake; Satoshi Anai; Takeshi Inoue; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Cancer       Date:  2017-09-02       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.